The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin’s lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Principal Investigator:
Ivan Kirov, MD

Research Coordinator:
Dorian Chan, RN
(714) 509-8646

Visit for more information about this trial.

  • Clinical Trial Info
  • IRB Number: 180213
  • Sponsor: COG/BMS
  • Protocol Number: AHOD1721/BMS CA209-744
  • NCT Number: NCT03458728
  • Research Type: Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors
  • Phase: II
  • Status: Active

Key Inclusion Criteria:

  • Classic Hodgkin Lymphoma (cHL), relapsed or refractory
  • Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
  • One prior anti-cancer therapy that did not work

Key Exclusion Criteria:

  • Active, known, or suspected autoimmune disease or infection
  • Active cerebral/meningeal disease related to the underlying malignancy
  • More than one line of anti-cancer therapy or no treatment at all
  • Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
  • Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)